This transcript has been edited for clarity.
Hello. I am Dr JoAnn Manson, professor of medicine at Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts. I'd like to talk with you about two recent reports, one in JAMA Cardiology[1] and one in Obstetrics & Gynecology,[2] that highlight the sobering relationship between preeclampsia or hypertensive disorders of pregnancy (HDP) and maternal cardiovascular events, as well as provide strong support for the preventability of these complications.
The first study[1] was a prospective, population-based cohort study from Norway, where they followed about 24,000 pregnant women, among whom 9% (about 2200) had an HDP. They documented that the subsequent risk for a cardiovascular event was increased 60% in these women—about a doubling in the risk for myocardial infarction in women with a HDP. They were interested in looking at the percentage of excess risk attributable to conventional risk factors and they documented that close to 80% of the excess risk was related to elevated blood pressure measured during follow-up or to elevated body mass index (BMI), either overweight or obese, suggesting at least two very important targets for reducing the risk for these cardiovascular complications.
The second study[2]was from California, a statewide study looking at pregnancy-related maternal death.
Polymorphic Eruption of Pregnancy
COMMENTARY
Preventing Fatal Maternal Stroke and Other CV Events
JoAnn E. Manson, MD, DrPH
DisclosuresJuly 25, 2019
This transcript has been edited for clarity.
Hello. I am Dr JoAnn Manson, professor of medicine at Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts. I'd like to talk with you about two recent reports, one in JAMA Cardiology[1] and one in Obstetrics & Gynecology,[2] that highlight the sobering relationship between preeclampsia or hypertensive disorders of pregnancy (HDP) and maternal cardiovascular events, as well as provide strong support for the preventability of these complications.
The first study[1] was a prospective, population-based cohort study from Norway, where they followed about 24,000 pregnant women, among whom 9% (about 2200) had an HDP. They documented that the subsequent risk for a cardiovascular event was increased 60% in these women—about a doubling in the risk for myocardial infarction in women with a HDP. They were interested in looking at the percentage of excess risk attributable to conventional risk factors and they documented that close to 80% of the excess risk was related to elevated blood pressure measured during follow-up or to elevated body mass index (BMI), either overweight or obese, suggesting at least two very important targets for reducing the risk for these cardiovascular complications.
The second study[2]was from California, a statewide study looking at pregnancy-related maternal death.
Medscape Ob/Gyn © 2019 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: JoAnn E. Manson. Preventing Fatal Maternal Stroke and Other CV Events - Medscape - Jul 25, 2019.
Tables
References
Authors and Disclosures
Authors and Disclosures
Author(s)
JoAnn E. Manson, MD, DrPH
Professor of Medicine, Michael and Lee Bell Professor of Women's Health, Harvard Medical School; Chief, Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Past President, North American Menopause Society, 2011-2012
Disclosure: JoAnn E. Manson, MD, DrPH, has disclosed the following relevant financial relationships:
Received study pill donation and infrastructure support from: Mars Symbioscience (for the COSMOS trial)